Alyeska Investment Group L.P. Sells 347,713 Shares of Abbott Laboratories $ABT

Alyeska Investment Group L.P. lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 59.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 235,000 shares of the healthcare product maker’s stock after selling 347,713 shares during the quarter. Alyeska Investment Group L.P.’s holdings in Abbott Laboratories were worth $31,173,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories during the 1st quarter valued at $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the 1st quarter valued at $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories during the 4th quarter valued at $32,000. Finally, JCIC Asset Management Inc. acquired a new stake in Abbott Laboratories during the 1st quarter valued at $32,000. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 0.4%

NYSE ABT opened at $132.01 on Thursday. The stock has a fifty day moving average of $130.73 and a 200-day moving average of $131.36. The stock has a market capitalization of $229.75 billion, a P/E ratio of 16.54, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the firm earned $1.14 EPS. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date was Tuesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company dropped their price target on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Raymond James Financial dropped their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Royal Bank Of Canada raised their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Evercore ISI lifted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.